Gold bars to be exempt from tariffs, White House clarifies
In addition to the sale, Singh acquired 3,786 shares of common stock on January 2 through the conversion of RSUs. Each RSU converted into one share of Accolade's common stock. Following these transactions, Singh holds a total of 818,479 shares directly and 651,619 shares indirectly through Avanti Holdings, LLC, where he has voting and investment power. With the company's next earnings report due on January 9, InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of the company's financial health and growth prospects. With the company's next earnings report due on January 9, InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of the company's financial health and growth prospects.
In addition to the sale, Singh acquired 3,786 shares of common stock on January 2 through the conversion of RSUs. Each RSU converted into one share of Accolade's common stock. Following these transactions, Singh holds a total of 818,479 shares directly and 651,619 shares indirectly through Avanti Holdings, LLC, where he has voting and investment power.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been the focus of several analyst firms following its strong second-quarter 2025 performance. The company exceeded revenue expectations with a total of $106.4 million and surpassed its adjusted EBITDA guidance. Wells Fargo (NYSE:WFC) revised Accolade's price target downwards to $6.00 due to concerns over delayed deal closures, while maintaining an Equal Weight rating. Meanwhile, Stephens, Canaccord Genuity, Truist Securities, and BofA Securities also adjusted their price targets but held onto their Buy ratings.
Stephens adjusted its model to reflect a 12% revenue growth for Accolade in fiscal years 2025 and 2026, while Canaccord Genuity expressed confidence in Accolade's ability to meet performance guarantees despite the company's third-quarter guidance falling below estimates. Truist Securities reduced its price target to $7.50, and BofA Securities reduced its target to $5.75, both firms maintaining a Buy rating on the company's stock.
Accolade's management has expressed optimism about a strong pipeline with diversification across employers, health plans, and government segments. However, slower revenue growth is anticipated in fiscal year 2026 due to staggered launches. The company has confirmed its fiscal year 2025 revenue guidance between $460 million to $475 million and projected a positive adjusted EBITDA of $15 million to $20 million. These recent developments reflect the company's current financial performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.